Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 31:8:631.
doi: 10.3389/fimmu.2017.00631. eCollection 2017.

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

John P Veluchamy  1   2 , Nina Kok  2 , Hans J van der Vliet  1 , Henk M W Verheul  1 , Tanja D de Gruijl  1 , Jan Spanholtz  2
Affiliations
Review

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

John P Veluchamy et al. Front Immunol. .

Abstract

Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant antitumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.

Keywords: adoptive natural killer cell therapy; allogeneic natural killer cells; autologous natural killer cells; hematopoietic stem cell transplantation; natural killer cell biotech companies; natural killer cell combinatorial studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of natural killer (NK) cell clinical milestones from academia and biotech industries.
Figure 2
Figure 2
Strategies to augment natural killer (NK) cell functions.
See this image and copyright information in PMC

References

    1. Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ. Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther (2017) 17(3):313–24. 10.1080/14712598.2017.1271874 - DOI - PMC - PubMed
    1. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol (2001) 22(11):633–40. 10.1016/S1471-4906(01)02060-9 - DOI - PubMed
    1. Campbell KS, Hasegawa J. NK cell biology: an update and future directions. J Allergy Clin Immunol (2013) 132(3):536–44. 10.1016/j.jaci.2013.07.006 - DOI - PMC - PubMed
    1. Zhang J, Basher F, Wu JD. NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol (2015) 6:97. 10.3389/fimmu.2015.00097 - DOI - PMC - PubMed
    1. de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol (2014) 92(3):237–44. 10.1038/icb.2013.95 - DOI - PubMed